Gregory Burshtein - 28 May 2024 Form 3 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief of R&D
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
28 May 2024
Net transactions value
$0
Form type
3
Filing time
07 Jun 2024, 16:05:57 UTC
Next filing
18 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 75,126 28 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 20,000 $3.97 Direct F2
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 18,900 $2.14 Direct F3
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 51,000 $3.61 Direct F4
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 45,000 $2.57 Direct F5
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 65,000 $0.7950 Direct F6
holding ENTX Stock Option (right to buy) 28 May 2024 Ordinary Shares, par value NIS 0.0000769 per share 150,000 $1.99 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a grant of 25,126 stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
F2 The options vest over a four-year period that commenced on January 17, 2019, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F3 The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F4 The options vest over a four-year period that commenced on April 7, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F5 The options vest over a four-year period that commenced on April 28, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F6 The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F7 The options vest over a three-year period that commenced on April 19, 2024, with 33% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney